Tag Archives: Regor

Diamyd Type C Meeting Updates; Kardigan Launches as CV Company; Regor Topline Ph2a Results for Oral GLP-1RA

Three cardiometabolic-related news items have been observed: Diamyd provided details on the meeting minutes from its Type C meeting with FDA regarding accelerated approval of Diamyd (view press release); Kardigan announced its launch as a CV-focused company (view press release); and Regor Therapeutics announced topline Ph2a results for its oral QD GLP-1RA in obesity (view press release). Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.
Register

Already a member? Log in here

Senseonics, Akero, Amarin Q4 ’23 Earnings; Viking Commences $550M Public Offering; Pfizer and Regor Initiate Oral GLP-1RA Studies; Virta Published GLP-1RA Discontinuation Results

A series of cardiometabolic-related news items have been observed from Senseonics, Akero, Viking, Pfizer, Regor Therapeutics, Virta Health, and Amarin. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.
Register

Already a member? Log in here

Lilly Partners with Regor Therapeutics for Metabolic Drug Discovery

Lilly announced it has entered into a multi-year research agreement with Regor Therapeutics Group for the discovery, development, and commercialization of novel therapies for metabolic disorders. For context, Regor Therapeutics Group (view website) is a Chinese-based pharma company using Computer Accelerated Rational Discovery (CARD) to develop new medicines. Interestingly, the press release states, “Regor’s technology will also allow Lilly to further accelerate innovation and deliver breakthrough therapies in obesity and diabetes,” suggesting the partnership is broader than obesity and diabetes. Below, FENIX provides thoughts and insights on the Regor partnership.

This content is for Read Less members only.
Register

Already a member? Log in here